Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > Articles online first > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Dec 09

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 Dec 09

DOI: 10.23736/S1824-4785.21.03426-9

Copyright © 2021 EDIZIONI MINERVA MEDICA

language: English

Theragnostic in neuroendocrine tumors

Irene MARINI 1, Maddalena SANSOVINI 1, Alberto BONGIOVANNI 2, Silvia NICOLINI 1, Ilaria GRASSI 1, Nicoletta RANALLO 2, Manuela MONTI 3, Valentina DI IORIO 4, Luca GERMANÓ 1, Paola CAROLI 1, Anna SARNELLI 5, Giovanni PAGANELLI 1, Stefano SEVERI 1

1 Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì-Cesena, Italy; 2 Osteoncology and Rare Tumors Center (CDO-TR) IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì-Cesena, Italy; 3 Biostatistics and Clinical Sperimentations Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì-Cesena, Italy; 4 Oncology Pharmacy, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì-Cesena, Italy; 5 Medical Physics, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Forlì-Cesena, Italy


PDF


In the last few decades incidence and prevalence of neuroendocrine tumours has been increasing. The theragnostic approach, that allows the diagnosis and treatment of different neoplasms with the same ligand, is a typical nuclear medicine tool. Applied for years, is also pivotal in Neuroendocrine Tumours (NETs) where has improved the diagnostic accuracy and therapeutic efficacy with impact on patient’s survival. Theragnostic also allows the identification of important prognostic factors such as tumour location and burden, presence of liver metastases and intensity of Somatostatin Receptors (SSTR) expression to consider in new and possibly combined studies to ameliorate patient’s outcome. Moreover, the possibility to evaluate receptor expression even in non-NET malignancies has “de facto” widened the possible indications for PRRT. We believe that this innovative therapeutic approach will be implemented in next years by radiomics and biological tumours characterization to better address PRRT applications.


KEY WORDS: Theragnostic; PRRT; 68Ga dota-peptides PET; Lutetium; GEP-NETs

top of page